Fair value (multi-method)
Four independent methods triangulate what ALNY is worth. The headline is the Forward-DCF intrinsic value at a normalized growth rate; the margin of safety compares it to the current price.
Estimated fair value (Forward DCF)
$23,342.23
Method range
$16.80 – $23,342.23
median $809.45
Valuation methods
Each method’s implied fair value per share and its upside versus the current price. Missing methods (no analyst coverage, negative earnings, etc.) are shown as “—”.
| Method | Fair value | Upside vs price |
|---|---|---|
| Forward DCF | $23,342.23 | +7,602.44% |
| Exit multiple | $1,173.24 | +287.14% |
| Analyst target | $445.67 | +47.06% |
| Graham number | $16.80 | -94.46% |
- Forward DCF$23,342.23
- Exit multiple$1,173.24
- Analyst target$445.67
- Graham number$16.80
Stock price
$303.05
FCF / share (TTM)
$0.37
3Y FCF CAGR
220.8%
Fair value @ hist. growth
$710367.23
This analysis is for informational purposes only and is not financial advice. Scenario prices and DCF-style figures depend on your assumptions and data from public filings and estimates. They are not forecasts of future returns.
Implied FCF growth
46.7%
per year over your projection horizon
Margin of safety 100.0% vs hist-growth DCF
Historical 3Y CAGR
220.8%
Your model implies
46.7%
Analyst consensus is EPS-only — no comparable FCF / share estimate to show on this basis.
Model inputs
Move sliders to test how the reverse DCF reacts. Historical-growth markers show where the company has actually grown over the last cycle.
Undiscounted FCF per share over 10 years at 221% annual growth.
Cumulative FCF covers the current price by year 6.
Sensitivity — implied growth vs your assumptions
Each cell shows the per-share growth rate the market would need to justify the current price at that combination of discount rate (rows) and terminal growth (columns). Your selected inputs are highlighted.
| Row axis: discount rate. Column axis: terminal growth.Terminal g →↓ Discount | 1.5% | 2.0% | 2.5% | 3.0% | 3.5% |
|---|---|---|---|---|---|
| 5.0% | 45.1% | 43.0% | 40.6% | 37.6% | 33.8% |
| 5.1% | 45.5% | 43.4% | 41.0% | 38.1% | 34.4% |
| 6.1% | 50.2% | 48.5% | 46.7% | 44.6% | 42.2% |
| 7.1% | 54.3% | 52.9% | 51.4% | 49.8% | 48.0% |
| 8.1% | 58.0% | 56.8% | 55.6% | 54.2% | 52.7% |
Historical multiples
Each bar is the trailing five-year range (low left, high right). Filled portion runs from low to today; the dot marks today; the small tick marks the five-year median. Low, median, and high are listed under each bar.
PEG
5.37
Demanding vs growth
Net cash
$379M
Total debt − cash
Beta
0.30
Vs market benchmark
Frequently asked questions
Alnylam Pharmaceuticals (ALNY) Key Financials
Charts, filings, and peer comparison for every metric
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation